 Homology Medicines NASDAQ:FIXX was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research note issued on Tuesday, Zacks.com reports. The firm presently has a 17.00 target price on the stock. Zacks Investment Researchs target price points to a potential upside of 21.34 from the stocks current price. According ... 